Doximity Faces Investigation Over Alleged Misrepresentations

Doximity, Inc., a digital platform for medical professionals that combines healthcare news, workflow products, and clinician networking, is facing scrutiny over potential misrepresentations in its financial disclosures and advertising practices. The scrutiny comes in the form of an ongoing investigation by Grabar Law Office on behalf of long-term shareholders.

According to the recently filed federal securities class action, Michigan Laborers' Pension Fund v. Doximity Inc., et al., Case No. 3:26-cv-10529, in the United States District Court for the Northern District of California, Doximity's officers and directors may have breached their fiduciary duties. The complaint alleges that the company overstated the impact of its Newsfeed on revenue growth, claimed to be gaining market share against competitors, and misrepresented the engagement levels of its users.

Specifically, the complaint states that Doximity repeatedly attributed its growth to record engagement on its Newsfeed and represented that it was outperforming competitors. However, it is alleged that these statements were materially false or misleading. The company is accused of:

The allegations were first revealed through a series of disclosures. On November 6, 2025, Doximity expressed caution regarding the outlook for advertising spending and indicated a slowdown in sales growth during the second half of fiscal 2026. This disclosure caused Doximity's share price to decline by $8.29 per share, or 13%.

On February 5, 2026, the company lowered its fiscal 2026 revenue guidance and reported that sales growth had decelerated while net income had contracted. Analysts subsequently raised concerns that the company's slowing growth could reflect a loss of market share to competitors. This led to a further decline in Doximity's share price, with shares allegedly falling another $5.59 per share, or 17%.

Finally, on May 13, 2026, Doximity announced that it had missed its already-reduced revenue guidance and projected significantly slower growth for fiscal 2027. According to the complaint, Doximity's stock fell another 23%, from $23.39 on May 13 to $18.01 on May 14, 2026.

Grabar Law Office is investigating whether Doximity's officers and directors caused or permitted the company to make allegedly false or misleading statements, failed to adequately oversee the company's operations and public disclosures, or otherwise breached fiduciary duties owed to the company and its shareholders. The law office is urging long-term shareholders who purchased or otherwise acquired Doximity shares before August 8, 2024, and continue to hold shares today, to contact them at [email protected] or call 267-507-6085 to learn more about seeking corporate reforms, the return of funds back to the company, and a court-approved incentive award at no cost to the shareholders.